By Anthony O. Goriainoff

 

AstraZeneca PLC said Monday that high-level results from the AZD7442 long-acting antibody's Phase 3 trial showed a statistically significant reduction in the risk of developing severe Covid-19 or death.

The U.K. pharmaceutical company said the trial met its primary endpoint, and that AZD7442 was the only long-acting antibody combination shown to both prevent and treat Covid-19.

"These important results for AZD7442... add to the growing body of evidence for use of this therapy in both prevention and treatment of Covid-19. An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," the company said.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

October 11, 2021 02:29 ET (06:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ott 2021 a Nov 2021 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Nov 2020 a Nov 2021 Clicca qui per i Grafici di Astrazeneca